[1]
|
J. Lindholm, S. Juul, J. O. Jorgensen, J. Astrup, P. Bjerre, U. Feldt-Rasmussen, C. Hagen, J. Jorgensen, M. Kosteljanetz, L. Kristensen, et al., “Incidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study,” The Journal of Clinical Endocrinology & Metabolism, Vol. 86, No. 1, 2001, pp. 117-123.
doi:10.1210/jc.86.1.117
|
[2]
|
J. Newell-Price, X. Bertagna, A. B. Grossman and L. K. Nieman, “Cushing’s Syndrome,” Lancet, Vol. 367, No. 9522, 2006, pp. 1605-1617.
doi:10.1016/S0140-6736(06)68699-6
|
[3]
|
D. J. Torpy, N. Mullen, I. Ilias, et al., “Association of Hypertension and Hypokalemia with Cushing’s Syndrome Caused by Ectopic ACTH Secretion: A Series of 58 Cases,” Annals of the New York Academy of Sciences, Vol. 970, No. 1, 2002, pp. 134-144.
doi:10.1111/j.1749-6632.2002.tb04419.x
|
[4]
|
J. P. Aniszewski, W. F. Young Jr., G. B. Thompson, C. S. Grant and J. A. van Heerden, “Cushing Syndrome Due to Ectopic Adrenocorticotropic Hormone Secretion,” World Journal of Surgery, Vol. 25, No. 7, 2001, pp. 934-940.
doi:10.1007/s00268-001-0032-5
|
[5]
|
M. F. Nijhoff, O. M. Derkers, L. J. Vleming, J. W. A. Smit, J. A. Romijn and A. M. Pereira, “ACTH-Producing Pheocromocytoma: Clinical Considerations and Concise Review of the Literature,” European Journal of Internal Medicine, Vol. 20, No. 7, 2009, pp. 682-685.
doi:10.1016/j.ejim.2009.08.002
|
[6]
|
M. Mannelli, J. W. M. Lenders, K. Pacak, G. Parenti and G. Eisenhofer, “Subclinical Phaeochromocytoma,” Best Practice and Researche Clinical Endocrinology and Metabolism, Vol. 26, No. 4, 2012, pp. 507-515.
|
[7]
|
P. M. Stewart, “Mineralocorticoid Hypertension,” Lancet, Vol. 353, No. 9161, 1999, pp. 1341-1347.
doi:10.1016/S0140-6736(98)06102-9
|